FilingsTodayTeva Pharmaceutical Industries
At a glance
Teva Pharmaceutical Industries reported 2025 revenue of $17.26B, up 4.3% from $16.54B in 2024. Over 4 years since 2021 ($15.88B), that is growth of about 2.1% a year. Operating margin was 12.5%, up from 10.8% in 2021. 2025 was the highest revenue year in this period. The company posted a loss in 2022 and 2024.
In the last 12 months 14 insiders reported 0 open-market purchases and 45 sales ($112.7M). 23 of the sales were made under pre-arranged 10b5-1 plans. The largest was a sale of $15.3M by President and CEO Richard D Francis on Feb 18, 2026.
Teva Pharmaceutical Industries filed 13 current reports (Form 8-K) in the last 12 months, most often for results of operations (5), other events (3), material agreement (2) and new financial obligation (2). The latest officer or director change was reported on Oct 29, 2026. It reported a material agreement or a completed acquisition or disposal 2 times.
4 of the 20 investors tracked here held Teva Pharmaceutical Industries at the last quarter end, worth $128.8M combined. It is the largest weight for Duquesne Family Office (0.5% of its portfolio), followed by Bridgewater Associates (0.2%). Added: Bridgewater Associates and National Pension Service (Korea). Reduced: Duquesne Family Office.
Annual results
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | $417M | -$2.45B | -$559M | -$1.64B | $1.41B |
| Diluted EPS | $0.38 | $-2.20 | $-0.50 | $-1.45 | $1.21 |
Fiscal year ends Dec 31 · incorporated in L3
Tracked investors holding (13F)
Weight is the share of each investor's portfolio, as of the quarter end.
Current reports (8-K, last 12 months)
Insider open-market trades (last 12 months)
Source: SEC EDGAR. How figures are combined